RESUMEN
The authors provide an overview of Turkey's healthcare financing. After comparing financing data on Turkey and other Organization for Economic Cooperation and Development (OECD) member countries, they examine Turkey's performance on a wide range of healthcare input and outcome indicators using descriptive data drawn from the World Health Organization, World Bank, OECD, and Turkish Statistical Institute. The data analysis shows that Turkey ranks low by a number of key healthcare indicators across the OECD countries. Empirical analysis suggests that although many factors are associated with improvements in healthcare outcomes, a significant part of changes in life expectancy at birth are associated with higher spending on healthcare.
Asunto(s)
Financiación Gubernamental/tendencias , Gastos en Salud/tendencias , Calidad de la Atención de Salud/tendencias , Comparación Transcultural , Países Desarrollados/economía , Países en Desarrollo/economía , Europa (Continente) , Financiación Gubernamental/estadística & datos numéricos , Gastos en Salud/estadística & datos numéricos , Investigación sobre Servicios de Salud , Humanos , Esperanza de Vida/tendencias , Calidad de la Atención de Salud/economía , Calidad de la Atención de Salud/estadística & datos numéricos , TurquíaRESUMEN
OBJECTIVES: To determine the accuracy of patients' electronic medical record (EMR) drug profiles, to assess the relationship of copayment status with errors of commission and omission within drug profiles, and to evaluate the association between errors of commission in primary and secondary sections of the drug profiles. STUDY DESIGN: Cross-sectional analysis of patients' EMR drug profiles at a 46-bed hospital in Washington state. METHODS: Patients' drug profiles were compared against hospital staff interviews. Drug profiles listing each medication the patient was taking, without listing drugs the patient was not taking, exhibited perfect accuracy. We evaluated associations between errors of commission and omission, copayment status between errors of commission and omission, and associations between errors of commission in primary and secondary sections of the drug profiles. RESULTS: Demographics of study patients are similar to previously published research, and accuracy outcomes seem to be better than those of previously published studies. Fifty-six percent of drug profiles in our study hospital exhibited perfect accuracy. Errors of commission and omission were unassociated with copayment status; errors of commission in the primary section of the drug profile were unassociated with errors of commission in the secondary section of the drug profile. CONCLUSIONS: A medication reconciliation program may have led to a high rate of perfectly accurate drug profiles; while its purpose is to increase accuracy and to decrease errors, it may also assist in reducing adverse drug events. Results show that copayment amounts influence drug utilization; these may be associated with errors of commission and omission and not simply with copayment status.